NCT00126620View on ClinicalTrials.gov

Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

May 31, 2011

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

erlotinib hydrochloride

DRUG

sorafenib tosylate

Trial Locations (2)

L8V 5C2

Margaret and Charles Juravinski Cancer Centre, Hamilton

M5G 2M9

Princess Margaret Hospital, Toronto

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University Health Network, Toronto

OTHER

NCT00126620 - Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors | Biotech Hunter | Biotech Hunter